

Introducing OGIVRI[®],
the first biosimilar
trastuzumab for the
treatment of breast
and gastric HER2+
cancer approved
in Canada¹

 **Ogivri**[®]
trastuzumab
for injection



Mylan is committed to improving patient access to high-quality, affordable biological medicines.

Product Information

Product	DIN	Brand Reference
OGIVRI LYO 150MG 15ML	02474425	PrHerceptin [®]
OGIVRI LYO 440MG 50ML	02474433	PrHerceptin [®]

Ordering Information

Product	Pack Size	Mylan Code	UPC
OGIVRI LYO 150MG 15ML	1	400538480	 (01)00055873100869
OGIVRI LYO 440MG 50ML	1	400538484	 (01)00055873100876

For more information contact Mylan Customer Service at 1-800-575-1379

Indications for OGI[®]

OGI[®] is indicated for the treatment of HER2-positive tumours in the following cancers¹:

Early breast cancer	✓
Metastatic breast cancer	✓
Metastatic gastric cancer	✓



OGI[®] (trastuzumab) is a recombinant human monoclonal antibody (mAb) for the intravenous (IV) treatment of breast and gastric HER2+ cancer¹



OGI[®] is a biosimilar trastuzumab approved by Health Canada (HC), with demonstrated similarity to reference trastuzumab IV^{*1-3}



Mylan
ADVOCATE[®]

Providing patient support for OGI[®]

- Primary point of contact for all Healthcare Professionals and Drug Access Coordinators
- Easy to use portal to enroll patients
- Patient-centric approach to meet patient needs to minimize access barriers

- Reimbursement navigation
- Insurance coverage assistance for public and private drug plans
- Help with necessary paperwork
- Ongoing updates on patient reimbursement status

Additional support for patients:

- Infusion Services
- Ongoing updates on patient infusion status
- Information on OGI[®] and Biosimilars

Monday to Friday | 8:00 AM to 8:00 PM EST | Phone: 1-833-847-4323 | Fax: 1-833-794-2382
Email: BiosimilarsCanada@innomar-strategies.com / website: www.BiosimilarsCanadaPSP.com

For more information on Mylan's biosimilars go to mylanbiosimilars.ca

For more information about OGI[®] please visit [www.OGI[®].ca](http://www.OGI[®].ca)

[†]Herceptin[®] is a product of Hoffmann-La Roche Limited.

References: 1. [®]OGI[®] (trastuzumab) Product Monograph, May 3, 2019. BGP Pharma ULC. 2. Waller CF, Vutikulird A, Lawrence TE, Shaw A, Liu MS, Baczkowski M, et al. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-14010 vs. EU-trastuzumab and US-trastuzumab. Br J Clin Pharmacol 2018; 84(10): 2336-2343. 3. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 2017; 317(1): 37-47.

OGI[®] is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Mylan company. Mylan[®] is a registered trademark of Mylan Inc., used under permission by BGP Pharma ULC, a Mylan company. Copyright[®] 2019 BGP Pharma ULC, a Mylan company. All rights reserved. 85 Advance Road, Etobicoke, Ontario, M8Z 2S6 mylan.ca 1-844-596-9526